Dr. Jeffrey T. Apter

Psychiatry
Princeton Psychiatric Centers PA
256 Bunn Dr Ste 6, 
Princeton, NJ 
Princeton Psychiatric Centers PA
256 Bunn Dr Ste 6, 
Princeton, NJ 

Overview

Jeffrey Apter is a Psychiatrist practicing medicine in Princeton, New Jersey.

His clinical expertise encompasses Alzheimer's Disease, Dementia, and Attention Deficit Hyperactivity Disorder (ADHD).

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 11 clinical trials.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Princeton Psychiatric Centers PA
256 Bunn Dr Ste 6, Princeton, NJ 08540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

1 Total Publications

Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease.
Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease.
Journal: Current geriatrics reports
Published: November 07, 2015
Similar Doctors
Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

NYU Langone Psychiatry Associates

1 Park Ave Fl 8, 
New York, NY 
 (43.8 miles away)
212-263-3580
Languages Spoken:
English
See accepted insurances

Lenard Adler is a Psychiatrist practicing medicine in New York, New York. Dr. Adler is highly rated in 1 condition, according to our data. His clinical expertise encompasses Attention Deficit Hyperactivity Disorder (ADHD).

Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

Veterans Affairs New York Harbor Healthcare System-Manhattan Campus

423 E 23rd St, 
New York, NY 
 (43.6 miles away)
212-951-3294
Languages Spoken:
English

John Rotrosen is a Psychiatrist practicing medicine in New York, New York. Dr. Rotrosen is highly rated in 1 condition, according to our data. His clinical expertise encompasses Opioid Use Disorder.

Expertise in
3
conditions
Expertise in
3
conditions
Referral may be required

Princeton House

905 Herrontown Rd, 
Princeton, NJ 
 (1.0 miles away)
609-497-3356
Languages Spoken:
English
See accepted insurances

Robert Lasser is a Psychiatrist practicing medicine in Princeton, New Jersey. Dr. Lasser is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Postpartum Depression, Major Depression, Attention Deficit Hyperactivity Disorder (ADHD), and Schizophrenia.

Frequently Asked Questions about Dr. Jeffrey T. Apter

How do I make an appointment with Dr. Jeffrey T. Apter?

You can book an appointment with Dr. Jeffrey T. Apter by calling their office at 609-921-3555. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey T. Apter a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey T. Apter is classified as an Experienced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey T. Apter specialize in?

While Dr. Jeffrey T. Apter is a Psychiatry, they have specific expertise in Alzheimer's Disease, Dementia, and Attention Deficit Hyperactivity Disorder (ADHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Jeffrey T. Apter participate in research or clinical trials?

Yes. Dr. Jeffrey T. Apter has published 1 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Jeffrey T. Apter's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey T. Apter accept my insurance?

Dr. Jeffrey T. Apter accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 609-921-3555 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Apter's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile